ERBB3
ENSG00000065361
Target class
Kinase
Chromosome
12
Approved drugs
2
Clinical candidates (approved and in development)
17
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 17
- Chemical probe available
- Yes
- Other names
- HER3
- Target name
- ERBB3
- Gene name
- Erb-b2 receptor tyrosine kinase 3
- Gene symbol
- ERBB3
- Previous gene symbols
- LCCS2
- Protein name
- Receptor tyrosine-protein kinase erbB-3 (EC 2.7.10.1) (Proto-oncogene-like protein c-ErbB-3) (Tyrosine kinase-type cell surface receptor HER3)
- Gene biotype
- Protein coding
- Gene family
- Erb-b2 receptor tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 45
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 116.82
- Tissue specificity (Gini)
- 0.602
- Tissue specificity (tau)
- 0.858
- KEGG gene identifiers
- hsa:2065
- Protein interaction confidence
- 0.855447
- Protein interaction partners
- 94
- End position
- 56103505
- Start position
- 56076799
- Chromosome
- 12
- Strand
- Forward
- [Isoform 1]: Cell membrane
- Single-pass type I membrane protein.
- SUBCELLULAR LOCATION: [Isoform 2]: Secreted.
- Plasma membrane
Publication evidence
- PubMed 33497358
- Tissue specificity (tau)
- 0.857815
- Expression inequality (Gini)
- 0.601813
Expression in transcripts per million
- Nerve - Tibial
- 116.82
- Skin - Sun Exposed (Lower leg)
- 71.9
- Skin - Not Sun Exposed (Suprapubic)
- 66.65
- Esophagus - Mucosa
- 62.65
- Minor Salivary Gland
- 60.2
Expression in transcripts per million
- Nerve - Tibial116.82
- Skin - Sun Exposed (Lower leg)71.9
- Skin - Not Sun Exposed (Suprapubic)66.65
- Esophagus - Mucosa62.65
- Minor Salivary Gland60.2
- Brain - Spinal cord (cervical c-1)47.22
- Stomach45.57
- Vagina43.27
- Colon - Transverse42.51
- Prostate40.44
- Small Intestine - Terminal Ileum39.49
- Liver33.2
- Breast - Mammary Tissue20.31
- Pancreas20.01
- Colon - Sigmoid19.12
- Brain - Substantia nigra18.55
- Lung18.27
- Brain - Hippocampus17.37
- Brain - Putamen (basal ganglia)15.57
- Kidney - Cortex15.52
- Esophagus - Muscularis13.98
- Esophagus - Gastroesophageal Junction13.95
- Cervix - Ectocervix13.63
- Kidney - Medulla13.17
- Cervix - Endocervix12.41
And 29 more, listed on the interactive page.
- GO:0007162
- GO:0007165
- GO:0007169
- GO:0009968
- GO:0042127
- GO:0043491
- GO:0051048
- GO:0051402
- GO:0051897
- GO:0097192
- GO:0005576
- GO:0005886
- GO:0016323
- GO:0038143
- GO:0043235
- GO:0004713
- GO:0005515
- GO:0019838
- GO:0030296
- GO:0031625
- GO:0038132
- GO:0042802
- GO:0043125
- GO:0046982
Related records
Trials (295)
- 26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
- A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol
- A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors
- A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
- A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
- A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
- A Phase I Study to Assess the Pharmacokinetics of Metformin When Administered Alone and in Combination With Vandetanib
- A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)
- A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer
- A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer
- A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer
- A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
- A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC
- A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway
- A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study
- A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
- A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
- A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East Asia
Drugs (17)
- AMG-888 Receptor tyrosine-protein kinase erbB-3 inhibitor
- AV-203 Receptor tyrosine-protein kinase erbB-3 inhibitor
- CDX-3379 Receptor tyrosine-protein kinase erbB-3 inhibitor
- Duligotuzumab Receptor tyrosine-protein kinase erbB-3 inhibitor
- Elgemtumab Receptor tyrosine-protein kinase erbB-3 inhibitor
- Istiratumab Receptor tyrosine-protein kinase erbB-3 inhibitor
- KBP5209 Epidermal growth factor receptor inhibitor
- Lumretuzumab Receptor tyrosine-protein kinase erbB-3 inhibitor
- MM-111 ErbB-2/ErbB-3 heterodimer inhibitor
- Patritumab Receptor tyrosine-protein kinase erbB-3 inhibitor
- Patritumab deruxtecan Receptor tyrosine-protein kinase erbB-3 binding agent
- Poziotinib Epidermal growth factor receptor inhibitor
- Sapitinib Receptor tyrosine-protein kinase erbB-3 inhibitor
- Seribantumab Receptor tyrosine-protein kinase erbB-3 antagonist; Receptor tyrosine-protein kinase erbB-3 inhibitor
- Tarloxotinib Epidermal growth factor receptor inhibitor
- Vandetanib Epidermal growth factor receptor inhibitor
- Zenocutuzumab ErbB-2/ErbB-3 heterodimer inhibitor